The Food and Drug Administration will hold a public hearing on September 14 to examine issues surrounding the use of psychedelic drugs in supervised and supportive care settings, according to Jefferies.
The hearing is scheduled to run from 12:30 p.m. to 4:30 p.m. Eastern Time and will be open to public comment. A presiding officer will lead the proceeding alongside FDA panelists from the Center for Drug Evaluation and Research and additional federal partner panelists.
Separately, the agency has released final guidance on the development of psychedelic drugs, with a primary focus on generating efficacy data that regulators can interpret reliably. The finalized guidance expands recommendations intended to reduce bias and strengthen trial integrity.
The FDA identified several specific topics it plans to address during the hearing, including training and credentialing of providers, measures to promote patient safety, access considerations, and recommended practices for data collection and standardization. These discussion points are intended to help shape how experimental and approved therapies are administered in supervised settings.
The agency reiterated its commitment to advancing innovation while maintaining standards for safety, efficacy and product quality. In the guidance material and accompanying statements, the FDA noted progress in psychedelic drug development, citing the issuance of rare pediatric disease vouchers and breakthrough therapy designations for a list of compounds that includes psilocybin, MDMA, esketamine, d-psilocin, LSD and 5-Meo-DMT.
The public hearing is positioned to support the implementation of an executive order that directs the Department of Health and Human Services and the FDA to coordinate with other federal agencies on a unified federal effort related to psychedelics. The agency framed the session as part of that broader interagency work.
Key adjustments in the final 2026 guidance include a more flexible, risk-based approach to nonclinical studies. Notably, the threshold for relying on prior human experience was lowered to require what the agency calls adequate prior human exposure, a shift from the extensive exposure standard that appeared in the 2023 draft guidance.
The guidance also reduces dependence on traditional animal abuse-liability studies for evaluating abuse potential. Instead, sponsors may employ computational models that draw on chemical structure and molecular target information as part of their assessment strategies.
The hearing will accept comments from the public and convene a panel of FDA and federal partners to explore the practical and regulatory questions raised by supervised psychedelic treatments and the new guidance for development.